Regeneron extends $720M lease financing for headquarters by five years to 2027

REGENERON PHARMACEUTICALS, INC.

Five-year extension of $720M lease financing originally from 2017; new maturity March 3, 2027.
Yield on advances changed to one-month SOFR plus spread adjustment and margin tied to debt rating/leverage.
Lessee may extend another five years with all Participants' consent; prepayment allowed without premium.
Guarantors: Regeneron, Regeneron Healthcare Solutions, and Regeneron Genetics Center (joint and several).
Covenants mirror existing credit agreement: max total leverage ratio, min interest expense coverage, restricted payments test.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.